Drug Shortage Report for TEVA-TOBRAMYCIN
Report ID | 147231 |
Drug Identification Number | 02389622 |
Brand name | TEVA-TOBRAMYCIN |
Common or Proper name | TOBRAMYCIN INH SLN 60MG/ML 5ML |
Company Name | TEVA CANADA LIMITED |
Market Status | MARKETED |
Active Ingredient(s) | TOBRAMYCIN |
Strength(s) | 60MG |
Dosage form(s) | SOLUTION |
Route of administration | INHALATION INHALATION |
Packaging size | 56 |
ATC code | J01GB |
ATC description | AMINOGLYCOSIDE ANTIBACTERIALS |
Reason for shortage | Demand increase for the drug. |
Anticipated start date | |
Actual start date | 2021-10-13 |
Estimated end date | 2021-12-31 |
Actual end date | 2021-12-14 |
Shortage status | Resolved |
Updated date | 2021-12-17 |
Company comments | Will cover 100% of market through allocation to Est end Date. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v6 | 2021-12-17 | French | Compare |
v5 | 2021-12-17 | English | Compare |
v4 | 2021-10-21 | French | Compare |
v3 | 2021-10-21 | English | Compare |
v2 | 2021-10-14 | French | Compare |
v1 | 2021-10-14 | English | Compare |
Showing 1 to 6 of 6